COMPASS Pathways Plc Sponsored ADR CMPS 深 滬
等待開盤 03-26 09:30:00 美东时间
5.62
+0.400
+7.66%
華盛通- 最 高5.80
- 今 開5.31
- 成交量 203.44万股
- 最 低 5.31
- 昨 收 5.22
- 總市值 6.38亿
- 52周最高 8.90
- 市盈率 靜 --
- 換手率 1.79%
- 52周最低 2.25
- 委 比 69.09%
- 總股本 1.14亿
- 歷史最高 61.69
- 量 比 0.76
- 振 幅 9.39%
- 歷史最低 2.25
- 每 手 1
- 風險率 1.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Morgan Stanley Maintains Overweight on Compass Pathways, Lowers Price Target to $16
Morgan Stanley analyst Vikram Purohit maintains Compass Pathways (NASDAQ:CMPS) with a Overweight and lowers the price target from $18 to $16.
今天 01:37
Compass Pathways Q4 EPS $(1.00) Misses $(0.37) Estimate
Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.37) by 173.22 percent. This is a 58.73 percent decrease over losses of $(0.63) per share
03-24 19:37
Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate
Red Light Holland and Kala Bio have partnered to deploy Kala Bio’s Researgency.ai agentic AI platform to support the clinical development of PEX010, a patented botanical psilocybin drug candidate developed by Filament Health Corp. Red Light recently announced its acquisition of Filament, which includes PEX010 and its extensive intellectual property portfolio. The Researgency.ai platform will assist in clinical planning, protocol optimization, and...
03-18 13:00
Compass Pathways to Join Stifel Virtual CNS Forum Fireside Chat
Compass Pathways to Join Stifel Virtual CNS Forum Fireside Chat Compass Pathways management will attend the Stifel 2026 Virtual CNS Forum on March 17-18, 2026. The company will participate in a fireside chat on March 18, 2026 at 10:30am ET. Disclaimer: This news brief was created by Public Technolog
03-12 18:30
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
Issued on behalf of Cybin D/B/A Helus Pharma USANewsGroup.com News Commentary VANCOUVER, BC, March 9, 2026 /PRNewswire/ -- The central nervous system therapeutics sector is approaching a com...
03-09 22:50
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
HC Wainwright & Co. Maintains Buy on Compass Pathways, Raises Price Target to $70
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $40 to $70.
03-02 21:50
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
Issued on behalf of Helus Pharma VANCOUVER, BC, Feb. 26, 2026 /PRNewswire/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatm...
02-27 01:07
Compass Pathways raises $200M through warrant exercises
Compass Pathways (CMPS) said holders exercised 35,059,448 warrants issued on January 13, 2025, generating about $200M in proceeds for the company. As a result, Compass is issuing 15,160,619 American D...
02-26 20:37
Compass Pathways Announces Exercise Of 35,059,448 Warrants For Proceeds Of ~$200M
Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were issued on January 13,
02-26 19:40
